COMMUNIQUÉS West-GlobeNewswire

Glucotrack, Inc. Reminds Shareholders to Vote
28/10/2025
The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: [...]
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
28/10/2025
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third [...]
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
28/10/2025
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial [...]
AssistRx Named a Winner of the Orlando Sentinel Media Group’s Central Florida Top Workplaces 2025 Award
28/10/2025
Healthcare technology and patient solutions provider recognized as a Central Florida top employer for fifth consecutive year ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation [...]
R1 Welcomes Estelle Barnes to Lead Enterprise Customer Engagement and Partnerships
28/10/2025
MURRAY, Utah, Oct. 28, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the appointment of Estelle Barnes as the leader of R1’s Enterprise Customer [...]
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
28/10/2025
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programs To bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 [...]
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
28/10/2025
Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic Solution ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE [...]
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
28/10/2025
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and [...]
Entrada Therapeutics to Present at Upcoming Investor Conferences
28/10/2025
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in London [...]
Castle Biosciences to Participate in Upcoming Investor Conferences
28/10/2025
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management [...]
Verano Holdings Corp. Announces Shareholder Approval to Redomicile Parent Company from British Columbia to Nevada
28/10/2025
CHICAGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp . (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the plan the Company previously [...]
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
28/10/2025
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
28/10/2025
BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans [...]
Zag Bio™ Launches with $80 Million Financing to Advance Thymus-targeted Medicines for Autoimmune Diseases
28/10/2025
Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanism to induce central tolerance Lead program in Type 1 diabetes is [...]
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
28/10/2025
CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman [...]
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
28/10/2025
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel [...]
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
28/10/2025
Presentation will showcase the novel mechanisms of degradation of Amphista's Targeted Glues™, which recruit diverse E3 ligases, including DCAF16 and FBXO22, expanding the diversity and opportunity for TPD medicines. The [...]
KFSHRC inaugure la première usine de fabrication de thérapies géniques et cellulaires en Arabie saoudite
28/10/2025
RIYAD, Arabie saoudite, 28 oct. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre a annoncé qu’il ouvrirait la première usine d’Arabie saoudite pour la fabrication de thérapies génétiques [...]
Regeneron Reports Third Quarter 2025 Financial and Operating Results
28/10/2025
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD ® U.S. net sales increased 10% to $431 million [...]

Pages